RetinaLogik

Cover Block

Attribute	Details
Name	RetinaLogik
Tagline	Portable VR-based vision screening platform for accessible and efficient eye care.
Headquarters	Calgary, Canada
Founded	2021
Stage	Seed
Business Model	Hardware + Software
Industry	Healthtech
Technology	Hardware
Geography	North America
Growth Profile	Venture Scale
Founding Team	Academic Spinout
Funding Label	Seed (total disclosed ~$1,100,000)

Links

• Website: https://www.retinalogik.com/
• LinkedIn: https://www.linkedin.com/company/retinalogik

What an Investor Needs First

RetinaLogik is a Calgary-based startup building a portable, VR-based vision screening platform that addresses the challenge of accessible, low-cost eye care, validated by a $1.1 million funding round and Health Canada Class II medical device approval [BetaKit, February 2025]. Spun out from the University of Calgary in 2021 by Dr. Abdullah Sarhan and Julia St. Amand, the company developed the RVF200 headset, a software layer running on commercial VR hardware [University of Calgary, August 2023]. Patients self-administer visual field tests with guidance in over 35 languages, while specialists review results remotely via a web portal [retinalogik.com, retrieved 2024]. This approach decouples testing from stationary clinical equipment, targeting workflow improvements of up to 35% for clinics and expanding reach into rural communities, senior homes, and telehealth models [Angel Investors Ontario, February 2024].

CEO Abdullah Sarhan holds a PhD and led the underlying research, while COO Julia St. Amand manages business development and strategy [BetaKit, February 2025]. The seed financing, supported by a syndicate including York Angel Investors and UCeed, provides capital to execute on commercial deployments [Business Wire, March 2025]. Key milestones include scaling North American clinic deployments, pursuing additional regulatory approvals, and translating partnership discussions with NGOs and health authorities into contracted pilots [Trico Foundation, November 2021].

Data Accuracy: GREEN -- Core claims on funding, regulatory status, product, and team are confirmed by multiple independent sources including BetaKit, Business Wire, and the University of Calgary.

Taxonomy Snapshot

Axis	Classification
Stage	Seed
Business Model	Hardware + Software
Industry / Vertical	Healthtech
Technology Type	Hardware
Geography	North America
Growth Profile	Venture Scale
Founding Team	Academic Spinout
Funding	Seed (total disclosed ~$1,100,000)

Inside the Company

RetinaLogik began as a research project at the University of Calgary, where co-founder Dr. Abdullah Sarhan was completing his PhD in biomedical engineering. The company was formally spun out in 2021 after Sarhan and co-founder Julia St. Amand decided to pursue the venture full-time [University of Calgary, August 2023]. The technology originated from Sarhan's research trip to Uganda, which highlighted the need for portable vision screening tools in underserved communities [University of Calgary, August 2023]. The company is headquartered in Calgary, Canada [BetaKit, February 2025].

Key early milestones include acceptance into the Life Sciences Fellowship (LSF) accelerator program in March 2022 [University of Calgary, August 2023]. The company achieved Health Canada Class II medical device approval in early 2025 [BetaKit, February 2025] [Business Wire, March 2025]. This approval coincided with the closure of a $1.1 million seed funding round in March 2025 [BetaKit, February 2025].

Data Accuracy: GREEN -- Confirmed by University of Calgary, BetaKit, and Business Wire.

Under the Hood

The core product is a portable visual field testing system built on commercially available virtual reality hardware. RetinaLogik's RVF200 headset is the physical interface for a suite of vision screening tests [retinalogik.com, retrieved 2024]. The software loads onto standard VR headsets, allowing patients to self-administer tests with guidance in over 35 languages [retinalogik.com, retrieved 2024] [University of Calgary, retrieved 2024]. Results are transmitted to a secure web portal for remote review by eye care specialists [Perplexity Sonar Pro Brief, retrieved 2024].

Health Canada Class II medical device approval validates the technology for diagnostic use in the Canadian market [BetaKit, February 2025]. The company claims its integrated approach can improve clinic workflow efficiency by up to 35% [retinalogik.com, retrieved 2024]. The device is reported to be in use in clinics across North America [Angel Investors Ontario, February 2024].

Data Accuracy: YELLOW -- Product features and regulatory status are confirmed by company and press sources; specific technical architecture and performance claims are sourced from the company.

Market Research

Access to vision care is a global challenge, with the market for decentralized testing reshaped by telehealth, aging demographics, and the maturation of consumer hardware. RetinaLogik targets the replacement of stationary, expensive clinical equipment with a portable, software-defined alternative.

Metric	Value
Global Ophthalmic Devices Market (2022)	$32.5B
Projected CAGR (2022-2030)	5.2%
Company's 2026 User Target	2,000,000 people

The global ophthalmic devices market was valued at approximately $32.5 billion in 2022 and is projected to grow at a compound annual rate of 5.2% through 2030 [Grand View Research, 2023]. Demand drivers include a structural shortage of eye care specialists, an aging global population, and the normalization of remote consultation models [University of Calgary, August 2023]. Regulatory forces are a critical gating factor, as evidenced by the company's recent Health Canada Class II medical device approval [BetaKit, February 2025].

Data Accuracy: YELLOW -- Market size figures are from an analogous third-party report; company-specific target is from a single early-stage interview.

Competition and Substitutes

RetinaLogik positions its portable VR headset as a bridge between clinical-grade accuracy and community-based accessibility. Primary incumbents are manufacturers of traditional perimeters, such as Zeiss and Heidelberg Engineering, which are expensive, bulky, and require dedicated space. RetinaLogik targets settings these devices cannot economically serve: rural clinics, community health centers, nursing homes, and telehealth programs [Perplexity Sonar Pro Brief, retrieved 2024].

Adjacent substitutes include smartphone-based vision screening apps and tablet-based perimeter tests, which generally lack the standardized, controlled testing environment and regulatory approvals required for definitive clinical diagnosis. RetinaLogik's defensible edge rests on its regulatory clearance as a Class II medical device [BetaKit, February 2025]. The company's distribution appears reliant on partnerships with NGOs and health authorities for community care models [Trico Foundation, November 2021].

Data Accuracy: YELLOW -- Competitive analysis is inferred from product positioning and market structure; no direct competitor names were confirmed in public sources.

Opportunity

The prize for RetinaLogik is a reconfiguration of the global vision screening market, shifting a traditionally hardware-bound, clinic-centric process to a software-defined, distributed service. Health Canada Class II approval validates the core technology for clinical use and removes a primary barrier to commercial adoption [BetaKit, February 2025]. By turning a fixed piece of clinic equipment into a portable software application, RetinaLogik addresses documented access barriers in rural communities and for patients with mobility challenges [University of Calgary, August 2023].

Scenario	What happens	Catalyst
Telehealth Standard	RetinaLogik becomes the preferred vision screening tool for large telehealth providers.	Partnership with a major national telehealth platform or insurer.
Public Health Deployment	Provincial or state health authorities adopt the platform for widespread community screening.	Successful pilot study with a public health unit.
Clinic Footprint Expansion	The RVF200 headset becomes a common piece of equipment in optometry clinics.	Distribution partnership with a major medical equipment supplier.

Data Accuracy: YELLOW -- The core regulatory approval and product claims are well-sourced. The growth scenarios are extrapolated from cited partnership models and early deployment claims.

Sources

1. [BetaKit, February 2025] RetinaLogik ready to execute on vision with $1.1-million financing, Health Canada Class II approval | https://betakit.com/retinalogik-ready-to-execute-on-vision-with-1-1-million-financing-health-canada-class-ii-approval/
2. [University of Calgary, August 2023] Researcher works to eliminate barriers to eye exams using artificial intelligence and virtual reality | https://ucalgary.ca/news/researcher-works-eliminate-barriers-eye-exams-using-artificial-intelligence-and-virtual-reality
3. [retinalogik.com, retrieved 2024] RetinaLogik - The new paradigm in vision testing | https://www.retinalogik.com/
4. [Angel Investors Ontario, February 2024] RetinaLogik - Within Sight, Within Reach | https://www.angelinvestorsontario.ca/companies/retinalogik
5. [Trico Foundation, November 2021] 10 Questions with RetinaLogik: A “Getting to Know Our Calgary…” | https://tricofoundation.ca/10-questions-with-retinalogik-a-getting-to-know-our-calgary/
6. [Business Wire, March 2025] RetinaLogik Secures $1.1 Million in Funding and Health Canada Class II Medical Device Approval | https://www.businesswire.com/news/home/20250317109280/en/RetinaLogik-Secures-1.1-Million-in-Funding-and-Health-Canada-Class-II-Medical-Device-Approval
7. [Startup Canada, December 2022] Empathetic Leadership with Julia St.Amand | https://www.startupcan.ca/blog/empathetic-leadership-with-julia-stamand/
8. [Grand View Research, 2023] Ophthalmic Devices Market Size, Share & Trends Analysis Report | https://www.grandviewresearch.com/industry-analysis/ophthalmic-devices-market